Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study

Stephanie Menghini-Mueller; Erich Studerus; Sarah Ittig; Ulrike Heitz; Laura Egloff; Christina Andreou; Lucia R. Valmaggia; Matthew J. Kempton; Mark van der Gaag; Lieuwe de Haan; Barnaby Nelson; Neus Barrantes-Vidal; Merete Nordentoft; Stephan Ruhrmann; Gabriele Sachs; Bart P. Rutten; Jim van Os; Anita Riecher-Rossler; Philip McGuire; Maria Calem; Stefania Tognin; Gemma Modinos; Eva Velthorst; Tamar C. Kraan; Daniella S. van Dam; Nadine Burger; Patrick McGorry; G. Paul Amminger; Christos Pantelis; Athena Politis; Joanne Goodall; Stefan Borgwardt; Charlotte Rapp; Renata Smieskova; Rodrigo Bressan; Ary Gadelha; Elisa Brietzke; Graccielle Asevedo; Elson Asevedo; Andre Zugman; Tecelli Dominguez-Martinez; Anna Racioppi; Paula Cristobal-Narvaez; Thomas R. Kwapil; Manel Monsonet; Mathilde Kazes; Claire Daban; Julie Bourgin; Olivier Gay; Celia Mam-Lam-Fook; EU-GEI High Risk Study Group

doi:10.1016/j.eurpsy.2019.04.007

Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study

Stephanie Menghini-Mueller, Erich Studerus, Sarah Ittig, Ulrike Heitz, Laura Egloff, Christina Andreou, Lucia R. Valmaggia, Matthew J. Kempton, Mark van der Gaag, Lieuwe de Haan, Barnaby Nelson, Neus Barrantes-Vidal, Merete Nordentoft, Stephan Ruhrmann, Gabriele Sachs, Bart P. Rutten, Jim van Os, Anita Riecher-Rossler^*, Philip McGuire, Maria CalemStefania Tognin, Gemma Modinos, Eva Velthorst, Tamar C. Kraan, Daniella S. van Dam, Nadine Burger, Patrick McGorry, G. Paul Amminger, Christos Pantelis, Athena Politis, Joanne Goodall, Stefan Borgwardt, Charlotte Rapp, Renata Smieskova, Rodrigo Bressan, Ary Gadelha, Elisa Brietzke, Graccielle Asevedo, Elson Asevedo, Andre Zugman, Tecelli Dominguez-Martinez, Anna Racioppi, Paula Cristobal-Narvaez, Thomas R. Kwapil, Manel Monsonet, Mathilde Kazes, Claire Daban, Julie Bourgin, Olivier Gay, Celia Mam-Lam-Fook, EU-GEI High Risk Study Group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.

Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.

Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.

Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful. (C) 2019 Published by Elsevier Masson SAS.

Original language	English
Pages (from-to)	52-59
Number of pages	8
Journal	European Psychiatry
Volume	59
DOIs	https://doi.org/10.1016/j.eurpsy.2019.04.007
Publication status	Published - Jun 2019

Keywords

Gender differences
Sex differences
Risk for psychosis
Comorbidity
Functioning
ULTRA-HIGH RISK
COMPREHENSIVE ASSESSMENT
MENTAL-DISORDERS
RATING-SCALE
DEPRESSION
RELIABILITY
VALIDITY
ANXIETY
ONSET
STATE

Access to Document

10.1016/j.eurpsy.2019.04.007

Cite this

Menghini-Mueller, S., Studerus, E., Ittig, S., Heitz, U., Egloff, L., Andreou, C., Valmaggia, L. R., Kempton, M. J., van der Gaag, M., de Haan, L., Nelson, B., Barrantes-Vidal, N., Nordentoft, M., Ruhrmann, S., Sachs, G., Rutten, B. P., van Os, J., Riecher-Rossler, A., McGuire, P., ... EU-GEI High Risk Study Group (2019). Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study. European Psychiatry, 59, 52-59. https://doi.org/10.1016/j.eurpsy.2019.04.007

@article{f13341714b354df39bd6de36ceba5645,

title = "Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study",

abstract = "Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful. (C) 2019 Published by Elsevier Masson SAS.",

keywords = "Gender differences, Sex differences, Risk for psychosis, Comorbidity, Functioning, ULTRA-HIGH RISK, COMPREHENSIVE ASSESSMENT, MENTAL-DISORDERS, RATING-SCALE, DEPRESSION, RELIABILITY, VALIDITY, ANXIETY, ONSET, STATE",

author = "Stephanie Menghini-Mueller and Erich Studerus and Sarah Ittig and Ulrike Heitz and Laura Egloff and Christina Andreou and Valmaggia, {Lucia R.} and Kempton, {Matthew J.} and {van der Gaag}, Mark and {de Haan}, Lieuwe and Barnaby Nelson and Neus Barrantes-Vidal and Merete Nordentoft and Stephan Ruhrmann and Gabriele Sachs and Rutten, {Bart P.} and {van Os}, Jim and Anita Riecher-Rossler and Philip McGuire and Maria Calem and Stefania Tognin and Gemma Modinos and Eva Velthorst and Kraan, {Tamar C.} and {van Dam}, {Daniella S.} and Nadine Burger and Patrick McGorry and Amminger, {G. Paul} and Christos Pantelis and Athena Politis and Joanne Goodall and Stefan Borgwardt and Charlotte Rapp and Renata Smieskova and Rodrigo Bressan and Ary Gadelha and Elisa Brietzke and Graccielle Asevedo and Elson Asevedo and Andre Zugman and Tecelli Dominguez-Martinez and Anna Racioppi and Paula Cristobal-Narvaez and Kwapil, {Thomas R.} and Manel Monsonet and Mathilde Kazes and Claire Daban and Julie Bourgin and Olivier Gay and Celia Mam-Lam-Fook and {EU-GEI High Risk Study Group}",

note = "Funding Information: This work was supported by the European Union (European Community{\textquoteright}s Seventh Framework Program [grant number HEALTH-F2-2010-241909 ; Project EU-GEI]). M.J.K. was supported by a Medical Research Council Fellowship [grant number MR/J008915/1 ]. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = jun,

doi = "10.1016/j.eurpsy.2019.04.007",

language = "English",

volume = "59",

pages = "52--59",

journal = "European Psychiatry",

issn = "0924-9338",

publisher = "Elsevier France-{\'E}ditions Scientifiques et Medicales Elsevier",

}

Menghini-Mueller, S, Studerus, E, Ittig, S, Heitz, U, Egloff, L, Andreou, C, Valmaggia, LR, Kempton, MJ, van der Gaag, M, de Haan, L, Nelson, B, Barrantes-Vidal, N, Nordentoft, M, Ruhrmann, S, Sachs, G, Rutten, BP, van Os, J, Riecher-Rossler, A, McGuire, P, Calem, M, Tognin, S, Modinos, G, Velthorst, E, Kraan, TC, van Dam, DS, Burger, N, McGorry, P, Amminger, GP, Pantelis, C, Politis, A, Goodall, J, Borgwardt, S, Rapp, C, Smieskova, R, Bressan, R, Gadelha, A, Brietzke, E, Asevedo, G, Asevedo, E, Zugman, A, Dominguez-Martinez, T, Racioppi, A, Cristobal-Narvaez, P, Kwapil, TR, Monsonet, M, Kazes, M, Daban, C, Bourgin, J, Gay, O, Mam-Lam-Fook, C & EU-GEI High Risk Study Group 2019, 'Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study', European Psychiatry, vol. 59, pp. 52-59. https://doi.org/10.1016/j.eurpsy.2019.04.007

TY - JOUR

T1 - Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study

AU - Menghini-Mueller, Stephanie

AU - Studerus, Erich

AU - Ittig, Sarah

AU - Heitz, Ulrike

AU - Egloff, Laura

AU - Andreou, Christina

AU - Valmaggia, Lucia R.

AU - Kempton, Matthew J.

AU - van der Gaag, Mark

AU - de Haan, Lieuwe

AU - Nelson, Barnaby

AU - Barrantes-Vidal, Neus

AU - Nordentoft, Merete

AU - Ruhrmann, Stephan

AU - Sachs, Gabriele

AU - Rutten, Bart P.

AU - van Os, Jim

AU - Riecher-Rossler, Anita

AU - McGuire, Philip

AU - Calem, Maria

AU - Tognin, Stefania

AU - Modinos, Gemma

AU - Velthorst, Eva

AU - Kraan, Tamar C.

AU - van Dam, Daniella S.

AU - Burger, Nadine

AU - McGorry, Patrick

AU - Amminger, G. Paul

AU - Pantelis, Christos

AU - Politis, Athena

AU - Goodall, Joanne

AU - Borgwardt, Stefan

AU - Rapp, Charlotte

AU - Smieskova, Renata

AU - Bressan, Rodrigo

AU - Gadelha, Ary

AU - Brietzke, Elisa

AU - Asevedo, Graccielle

AU - Asevedo, Elson

AU - Zugman, Andre

AU - Dominguez-Martinez, Tecelli

AU - Racioppi, Anna

AU - Cristobal-Narvaez, Paula

AU - Kwapil, Thomas R.

AU - Monsonet, Manel

AU - Kazes, Mathilde

AU - Daban, Claire

AU - Bourgin, Julie

AU - Gay, Olivier

AU - Mam-Lam-Fook, Celia

AU - EU-GEI High Risk Study Group

N1 - Funding Information: This work was supported by the European Union (European Community’s Seventh Framework Program [grant number HEALTH-F2-2010-241909 ; Project EU-GEI]). M.J.K. was supported by a Medical Research Council Fellowship [grant number MR/J008915/1 ]. Publisher Copyright: © 2019

PY - 2019/6

Y1 - 2019/6

N2 - Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful. (C) 2019 Published by Elsevier Masson SAS.

AB - Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful. (C) 2019 Published by Elsevier Masson SAS.

KW - Gender differences

KW - Sex differences

KW - Risk for psychosis

KW - Comorbidity

KW - Functioning

KW - ULTRA-HIGH RISK

KW - COMPREHENSIVE ASSESSMENT

KW - MENTAL-DISORDERS

KW - RATING-SCALE

KW - DEPRESSION

KW - RELIABILITY

KW - VALIDITY

KW - ANXIETY

KW - ONSET

KW - STATE

U2 - 10.1016/j.eurpsy.2019.04.007

DO - 10.1016/j.eurpsy.2019.04.007

M3 - Article

C2 - 31075522

SN - 0924-9338

VL - 59

SP - 52

EP - 59

JO - European Psychiatry

JF - European Psychiatry

ER -